LOS ANGELES & NEW YORK--(BUSINESS WIRE)--Foresite Capital, a multi-stage healthcare and life sciences investment firm with more than $3.5 billion in assets under management, today announced the promotion of Drs. Hyung Chun and Cindy Xiong to partner.

洛杉矶和纽约--（商业新闻短讯）--Foresite Capital是一家多阶段医疗保健和生命科学投资公司，管理资产超过35亿美元，今天宣布将Hyung Chun博士和Cindy Xiong提升为合伙人。

Foresite Capital recently announced the closing of a $900M fund that will continue the firm’s investing in groundbreaking technologies, ranging from novel therapeutics to companies at the intersection of technology and biotechnology. In their new roles, Xiong and Chun will lead investments across the Foresite portfolio focusing on a broad range of therapeutic areas, and continue to seek out new investment opportunities..

Foresite Capital最近宣布关闭一个9亿美元的基金，该基金将继续投资开创性的技术，从新型疗法到技术与生物技术交叉的公司。在他们的新角色中，熊和春将领导整个Foresite投资组合的投资，专注于广泛的治疗领域，并继续寻找新的投资机会。。

'Cindy and Hyung have demonstrated the ability to invest across both early and later stage opportunities working closely with entrepreneurs to build the next generation of healthcare companies,” said Jim Tananbaum, founder and CEO of Foresite Capital.

Foresite Capital创始人兼首席执行官吉姆·塔南鲍姆（JimTananbaum）表示：“辛迪（Cindy）和亨格（Hyung）证明了他们有能力跨越早期和晚期机会，与企业家密切合作，建立下一代医疗保健公司。”。

Michael Rome, managing director of Foresite Capital, added “They have both made a substantial impact across the Foresite portfolio leading to investments in novel areas, including next generation treatments for autoimmune diseases, innovative cellular therapies and medications for acute and chronic pain.”.

Foresite Capital董事总经理迈克尔·罗马（MichaelRome）补充道：“他们都在整个Foresite投资组合中产生了重大影响，导致了对新领域的投资，包括针对自身免疫性疾病的下一代治疗方法，创新的细胞疗法以及针对急性和慢性疼痛的药物。”。

Dr. Chun joined Foresite Capital in 2021 as a physician scientist from Yale School of Medicine, where he was a tenured professor and continues as an adjunct faculty member. He has published extensively in top journals including Nature, Science, New England Journal of Medicine, and is an inventor on multiple patents.

Chun博士于2021年加入Foresite Capital，成为耶鲁大学医学院（Yale School of Medicine）的一名医生兼科学家，曾任耶鲁大学终身教授，并继续担任兼职教员。他在包括《自然》、《科学》、《新英格兰医学杂志》在内的顶级期刊上发表了大量文章，并且是多项专利的发明人。

He has served in multiple academic leadership roles including as Co-Director of the Yale Cardiovascular Research Center, and in advisory roles to multiple biotech companies. Chun completed his residency in internal medicine and fellowship in cardiovascular disease at Stanford University, holds an M.D.

他曾担任多个学术领导职务，包括耶鲁心血管研究中心的联合主任，以及多家生物技术公司的顾问职务。Chun在斯坦福大学完成了内科住院医师和心血管疾病研究金，拥有医学博士学位。

from Johns Hopkins School of Medicine and an A.B. in Biochemical Sciences from Harvard College. He serves on the boards of multiple Foresite portfolio companies including Latigo Therapeutics..

来自约翰·霍普金斯医学院，并获得哈佛大学生化科学学士学位。他在包括Latigo Therapeutics在内的多家Foresite投资组合公司的董事会任职。。

'It has been an amazing journey working with our outstanding investment team since joining Foresite nearly three years ago,” said Chun. “I am eager to continue our mission to address critical unmet needs in healthcare and make transformative impacts on patients’ lives.'

“自从三年前加入Foresite以来，与我们杰出的投资团队合作是一段令人惊叹的旅程，”Chun说道。“我渴望继续我们的使命，解决医疗保健中未满足的关键需求，并对患者的生活产生变革性影响。”

Dr. Xiong joined Foresite Capital in 2019 as a member of the investment team, focusing on evaluating investment opportunities of private and public biotech companies. She serves on the boards of several portfolio companies including ImmPACT Bio and previously Xinthera Inc. (board observer, acquired by Gilead).

熊博士于2019年加入Foresite Capital，担任投资团队成员，专注于评估私人和公共生物技术公司的投资机会。她在几家投资组合公司的董事会任职，其中包括ImmPACT Bio和之前的Xinthera Inc.（董事会观察员，被Gilead收购）。

Prior to Foresite, Xiong earned her MBA in Healthcare Management from the Wharton School. She received her PhD in Biology from the University of Michigan, where she studied neural regeneration, and was a Helen Hay Whitney postdoctoral fellow at UCSF, developing new technologies for genome and cell engineering.

在Forestite之前，熊在沃顿商学院获得了医疗保健管理MBA学位。她在密歇根大学获得生物学博士学位，研究神经再生，是加州大学旧金山分校海伦·海伊·惠特尼博士后研究员，开发基因组和细胞工程新技术。

Xiong was the first scientist at Agenovir, where she led a team to develop CRISPR based therapeutics for HPV induced cancers..

熊是Agenovir的第一位科学家，她领导一个团队开发了基于CRISPR的HPV诱导癌症治疗药物。。

“Since joining Foresite, I have had the privilege to work with an incredibly talented team that has supported my growth and career trajectory over the last five years,” said Xiong. “I am particularly excited about my next chapter at Foresite and look forward to partnering with visionary biotech companies that develop innovative therapies for large unmet medical needs.”.

熊说：“自从加入Forestite以来，我有幸与一支才华横溢的团队合作，这支团队在过去五年中为我的成长和职业轨迹提供了支持。”。“我对我在Foresite的下一章感到特别兴奋，并期待着与有远见的生物技术公司合作，为未满足的医疗需求开发创新疗法。”。

About Foresite Capital

关于前陆资本

Foresite Capital is a multi-stage healthcare and life sciences investment firm with more than $3.5 billion in assets under management. The firm aims to address areas of unmet medical need by funding promising healthcare and life sciences businesses at all stages of their life cycles. Founded in 2011, Foresite Capital is based in the San Francisco Bay Area, Los Angeles, and New York City.

Foresite Capital是一家多阶段医疗保健和生命科学投资公司，管理资产超过35亿美元。该公司旨在通过在生命周期的各个阶段为有前途的医疗保健和生命科学业务提供资金，解决医疗需求未得到满足的领域。Foresite Capital成立于2011年，总部位于旧金山湾区、洛杉矶和纽约市。

For more information, please visit www.foresitecapital.com..

欲了解更多信息，请访问www.forestecapital.com。。